Introduction (words 2805/5000 Introduction through Discussion)
Patients with human epidermal growth factor receptor-2-positive (HER2+) breast tumors have greatly benefited from the development of trastuzumab, a humanized monoclonal antibody directed against HER2 (1) . Trastuzumab has proven to prolong the survival of women with metastatic breast cancer and significantly increase disease-free survival of patients with HER2+ early breast cancer (2, 3) . However, many women who receive trastuzumab for advanced disease develop tumor progression within one year, and 15-25% of women diagnosed with HER2+ early disease develop tumor relapse within three years, despite therapy (4) . Thus, identifying molecular markers that could predict the patients who are most likely to benefit from trastuzumab is an important research and clinical goal.
MYC is one of several markers reported to be involved in trastuzumab sensitivity and resistance. The MYC oncoprotein is a pleiotropic transcription factor and key regulator of cell growth, proliferation, metabolism, differentiation, apoptosis, and pathways that regulate genome stability and cell death (5, 6) . MYC has been shown to be overexpressed in breast cancer with reported frequencies between 12-100% depending on antibody/technique and cutpoint utilized, patient heterogeneity, and molecular subtype of the breast tumor(5-7). MYC acts as a downstream target of HER2-driven proliferative signals in breast cancer cells in vitro (8) , and deregulation of MYC contributes to breast cancer tumorigenesis and progression and is typically associated with poor outcomes (7) .
Additionally, MYC gene amplification has been reported to predict additional trastuzumab benefit in a retrospective analysis of the National Surgical Adjuvant Breast and Bowel Project Cooperative Group (NSABP) B31 adjuvant trial. NSABP B31 showed that patients with MYC/HER2 co-amplification (defined as average copies/nucleus >5.0) in their primary breast tumors, benefited significantly more (interaction p=0.007) from trastuzumab than patients with only HER2 amplification, although a significant benefit of trastuzumab was observed in both MYC amplified and non-amplified patients (9) .
Conversely, however, our results from the North Central Cancer Treatment Group (NCCTG) N9831(10) did not support the link between MYC gene amplification and benefit from trastuzumab strictly on the basis of MYC amplification defined as > 5.0 average copies/nucleus.
In the N9831 Intergroup adjuvant trastuzumab phase III trial, we observed differential benefit of trastuzumab in groups of HER2+ patients with <2.5 average MYC copies/nucleus and patients with alternative MYC and chromosome 8 copy number alterations (10) .
Considering that protein overexpression may be independent of gene amplification(5), we designed the translational component of the N9831 trial to also include an analysis of the role of MYC protein overexpression in trastuzumab sensitivity. We therefore evaluated the association between MYC protein expression and disease-free survival (DFS) of patients randomized to receive chemotherapy alone (Arm A) or chemotherapy with sequential (Arm B) or concurrent trastuzumab (Arm C) on N9831.
Materials and Methods

Patients
The N9831 trial (NCT00005970) was a phase III trial in which patients were randomized to three arms: Arm A: doxorubicin and cyclophosphamide followed by weekly paclitaxel; Arm B: same as Arm A but followed by 1 year of sequential trastuzumab; Arm C: same as Arm A but with 1 year concurrent trastuzumab, started the same day as weekly paclitaxel (Supplemental Figure 1) . Patients randomly assigned to the concurrent trastuzumab arm had a significantly increased DFS (P<.001; stratified hazard ratio [HR], 0.52; 95% CI, 0.45 to 0.60) and overall survival (OS)(P<.001; stratified HR, 0.61; 95% CI, 0.50 to 0.75) compared with patients assigned to the control arm (2) . In the N9831 comparison of sequential versus concurrent trastuzumab chemotherapy, there was an increase in DFS with concurrent Figure 2) . The number of patients represented on tissue microarrays (TMAs) with evaluable tissue cores was 1216 and the number of different patients with evaluable whole sections (WS) was 520 (Supplemental Figure 2) .
Tissue Microarrays and Whole Tissue Sections
TMAs were constructed as part of the translational study component of N9831 using an ATA-27 automated TMA construction system (Beecher Instruments, Silver Spring, MD) as described previously (10) . Each TMA contained control biopsies from non-neoplastic human liver, placenta, and tonsil tissues. Whole tissue sections from tumors not represented on TMAs were also examined. We evaluated the concordance between TMA and WS protein analyses of 86 independent breast tumors and observed a concordance of 90% and 92% using the minimum and maximum TMA scores, respectively, of nuclear 3+ staining in >30% invasive cells. Standard laboratory protocols were followed for immunohistochemistry (IHC) and quality control measures. Antigen retrieval was performed on deparaffinized whole or TMA sections (14) . We also evaluated cytoplasmic MYC protein expression because MYC has been observed in the cytoplasm of tumor cells(5), which has been shown to be correlated with increased survival of breast cancer patients (15) .
MYC Testing Methods
Statistical Methods
The primary endpoint of N9831 was disease-free-survival (DFS) and was defined as local, regional, or distant recurrence, contralateral breast cancer, another primary cancer (except squamous or basal cell carcinoma of the skin, carcinoma in situ of the cervix, or lobular carcinoma in situ of the breast), or death from any cause. Duration of DFS was defined as the time from registration to the first DFS event. DFS was estimated by the Kaplan-Meier method.
Comparisons between Arms A, B, and C within subgroups were performed using Cox positive and/or progesterone receptor positive vs. negative for both receptors). We tested MYC protein expression as a predictor for differential trastuzumab benefit between MYC subgroups using Cox proportional hazards models (also stratified by nodal status and hormone receptor status), which included a treatment arm by MYC subgroup interaction term. The maximum nuclear MYC protein expression of the WS or of the replicate TMA biopsies was used for all analyses associated with patient outcome.
Results
Study Patients
The 
Of 1736 patients with evaluable IHC analyses, 33% (n=574) had >30% invasive cells, 28% (n=494) had 10-30%, and 38% (n=668) had <10% invasive cells with 3+ nuclear staining ( Table   2 ). Nuclear and cytoplasmic 3+ staining had high agreement (81%; p<0.001), and the correlation between 3+ nuclear and 3+ cytoplasmic staining was 0.66 (p<0.001) ( Table 2) . No significant association was observed between 3+ nuclear staining and HER2 IHC staining (p= 0.10) ( Table 3 ). Representative staining patterns of MYC protein expression are shown in Figure 1 .
Associations between MYC protein expression and DFS
No significant differences in DFS were observed between MYC+ and MYC-patients in any of the three arms (Table 4) (Figure 2A-B) .
Comparing DFS between arms C and B, MYC+ and MYC-patients had HRs 0.56 (p=0.02) and 0.89 (p=0.49), respectively (interaction p=0.17) (Figure 2A-B) .
In addition, patients with nuclear MYC staining of 3+ in 0-9%, 10-30%, 31-60%, and 61- 
Discussion
MYC is a highly regulated and multifunctional transcription factor that regulates up to 15% of human genes and plays a central role in proliferation and malignant transformation of human and animal cells (16, 17) . Previous evidence from B31 and N9831 suggested that MYC gene copy number anomalies may be associated with additional benefit to adjuvant trastuzumab (9, 10). Reports have been inconsistent with regard to the association of MYC protein expression and both clinicopathological characteristics and prognosis (5 Overall, we found that MYC protein expression was heterogeneous and characterized by both cytoplasmic and nuclear localization. We observed nuclear MYC protein overexpression (defined as nuclear 3+ staining in >30% invasive cells) in tumors from 33% of N9831 patients with HER2+ breast cancer. Early studies using IHC have shown that ~ 50-100% of breast cancer cases have increased levels of MYC protein (5, 15, (18) (19) (20) (21) (22) (23) . In addition, strong MYC protein positivity was found in >20% nuclei in 45% of 440 primary breast tumors(24) and 70% (36/51) showed 1+ intensity staining(25) using the 9E10 clone employed in our present study.
Our study observed a lower incidence of 33% most likely due to our more strict cutoff criteria of 3+ staining in >30% nuclei and the fact that our patient population was HER2+ and not a general population of breast cancer patients.
We also observed strong (3+) cytoplasmic staining in malignant cells, which correlated with strong (3+) nuclear staining. Other groups have found predominant cytoplasmic localization of MYC (15, 19) , and this cytoplasmic staining has been associated with better survival (15) . These results support the idea of nuclear exclusion of MYC, which has been observed in high grade tumors, and could serve to attenuate select functions of MYC in later stages of disease progression (25, 26) .
In this analysis, MYC nuclear protein overexpression was associated with hormone receptor positivity, nodal positivity, and larger tumors with associated increase in mastectomy rates. In agreement with our findings, MYC protein expression has been correlated with positive nodes (20, 27) and with estrogen receptor positivity (19) . MYC also has been shown to be an estrogen-responsive gene (28) . Although a significant association has not been consistently observed between MYC protein expression and breast tumor size (5, 19) , MYC DNA levels (as detected by Southern blot) have been correlated with tumor size (5) MYC overexpression and tumor size in our study is consistent with MYC being a transcriptional activator of the cell proliferation pathway an additional marker for the assessment of tumor cell proliferation(5). In contrast, other studies have shown no significant associations with estrogen receptors (18, 20-22, 24, 29) , with lymph node status (15, 18, 20-22, 24, 29-32 ).
We did not observe a significant difference in outcome between patients with and without MYC protein overexpression within any treatment arm and specifically, the DFS of N9831 patients treated with chemotherapy only was similar, regardless of MYC protein overexpression. Although this suggests that MYC overexpression is not a marker for prognosis, the true prognostic significance of MYC protein overexpression cannot be addressed in this study as all patients were treated with chemotherapy, and subgroups of patients also received protocol-specified radiotherapy and/or hormonal therapy. We did observe that MYC overexpression was associated with larger tumors and nodal positivity, both of which are powerful prognostic indicators. In N9831, however, radiotherapy was directed based on surgery type and number of positive nodes. MYC overexpression was also associated with hormone receptor positivity, another disease characteristic which was used in directing additional therapy, namely hormonal therapy. Therefore, one possibility to explain similar DFS within arm regardless of MYC overexpression status is that MYC may have disparate prognostic impact in subtypes of breast cancer which washes out when treated differently and considered together.
Another possibility is that MYC overexpression confers a worse prognosis but perhaps a greater response to chemotherapy, making it an overall null biomarker in this chemotherapy-treated population.
Several investigations have found that higher expression of MYC protein correlated with poorer outcome (33) (34) (35) , while other studies have shown positive associations between MYC mRNA levels and survival(36) and between MYC protein levels and survival, most notably for node-negative patients (15) . Our findings are consistent with previous findings that demonstrated that MYC protein expression alone was not related to recurrence (30) 
supported by a limited number of studies that did not find associations between MYC expression and prognosis (19, 22) . Importantly, however, we observed a benefit of concurrent trastuzumab in patients with or without MYC protein overexpression.
We did observe a trend toward greater benefit from concurrent trastuzumab with increasing MYC protein expression. Trastuzumab has been shown to sensitize HER2- 
